Observational genetic study identifies unique types of MM

Aleksandar Sekulic named physician-in-chief at TGen

Aleksandar Sekulic was named physician-in-chief at the Translational Genomics Research Institute, part of City of Hope.

February 14, 2025

EU, China approve Sarclisa + standard of care for MM

The EU has approved Sarclisa (isatuximab-irfc) in combination with a standard-of-care regimen, bortezomib, lenalidomide, and dexamethasone, for the treatment of adult patients with newly diagnosed multiple myeloma ineligible for autologous stem cell transplant, based on data from the IMROZ phase III study.

January 24, 2025

Vol.51 No.03

In Brief

David Chung named director of clinical research at Northwell Health

Northwell Health appointed David J. Chung, a prominent oncologist-investigator, as director of clinical research at the Northwell Health Cancer Institute. In this newly created role, Chung also will serve as system chief of multiple myeloma across Northwell’s cancer centers.

January 17, 2025

Vol.51 No.02

In Brief

John Fryer joins TGen as professor, director of Center for Accelerated Nanotherapeutics

The Translational Genomics Research Institute, part of City of Hope, has announced the appointment of John D. Fryer as a professor in the Division of Bioinnovation and Genome Sciences and director of the newly established Center for Accelerated Nanotherapeutics.

January 17, 2025

Vol.51 No.02

Clinical Roundup

Tecvayli demonstrates potential in MM

Johnson & Johnson announced new frontline data featuring Tecvayli (teclistamab-cqyv) from two investigational studies in patients with newly diagnosed multiple myeloma in induction and maintenance settings.

December 13, 2024

Vol.50 No.46

Clinical Roundup

Blenrep combination shows OS benefit in MM

GSK plc announced statistically significant and clinically meaningful overall survival results from a planned interim analysis of the DREAMM-7 trial evaluating Blenrep (belantamab mafodotin) in combination with bortezomib plus dexamethasone versus daratumumab in combination with bortezomib plus dexamethasone as a second line or later treatment for relapsed or refractory multiple myeloma.

December 13, 2024

Vol.50 No.46

Observational genetic study identifies unique types of MM

YOU MAY BE INTERESTED IN

Aleksandar Sekulic named physician-in-chief at TGen

EU, China approve Sarclisa + standard of care for MM

David Chung named director of clinical research at Northwell Health

John Fryer joins TGen as professor, director of Center for Accelerated Nanotherapeutics

Tecvayli demonstrates potential in MM

Blenrep combination shows OS benefit in MM

Renew today!

Subscriber content

Never miss an issue!

Login